“… DAR (2006) and Addendum (2010), EFSA Conclusion (2010) | Delta 8,9 isomer of avermectin B1a (metabolite of abamectin) folpet | Facial fissures: cleft palate | 1.5 | 3 | ■■■■■ (1996b), Developmental toxicity, CD1 mouse, oral gavage | 0, 0.75, 1.5, 3.0 days 6–15 p.c. | DAR (2005) (abamectin) and Addendum (2016), EFSA Conclusion (2016) |
Deltamethrin | Skull vault agenesis: exencephaly | 4 | 16 | ■■■■■ (1977c), Developmental toxicity, New Zealand White rabbit, oral gavage | 0, 1, 4, 16 days 6–19 p.c | DAR (1998), Addendum (2002), (DRAR 2018), EC Review report (2002) |
| No indicators | 32 (10) | – | ■■■■■ (2001), Developmental toxicity, New Zealand White rabbit oral gavage | 0, 3, 10 , 32 days 6–28 p.c | DAR (1998), Addendum (2002), (DRAR 2018), EC Review report (2002) |
Dieldrin | Facial fissures: cleft palate | < 15 | 15 | ■■■■■ (1974), Developmental toxicity, CD1 mouse, oral gavage (b) | 0, 15 single oral dose on day 9 | JMPR (1994), EFSA PPR Panel ( 2007 ); JMPR (1989) |
| No indicators | 6 (6) | – | ■■■■■ (1975), Developmental toxicity CD1 mouse, oral gavage (b) | 0, 1.5, 3, 6 days 7–16 p.c. | JMPR (1... |
…”